Molecular mechanism of Buzhong Yiqi Decoction in coordination with Siβ-catenin in intervention against cisplatin resistance in lung adenocarcinoma by regulating the Wnt/β-catenin signaling pathway

Li He, Mu Qirui, Wang Zhe, Wang Ying, Yu Dan, Gao Yuan

PDF(1501 KB)
PDF(1501 KB)
Journal of Chongqing Medical University ›› 2024, Vol. 49 ›› Issue (02) : 147-152. DOI: 10.13406/j.cnki.cyxb.003420
Basic research

Molecular mechanism of Buzhong Yiqi Decoction in coordination with Siβ-catenin in intervention against cisplatin resistance in lung adenocarcinoma by regulating the Wnt/β-catenin signaling pathway

Author information +
History +

Abstract

Objective To investigate the molecular mechanism of Buzhong Yiqi Decoction in coordination with Siβ-catenin in intervention against cisplatin resistance in A549/DDP cells by regulating the Wnt/β-catenin signaling pathway. Methods The expression of β-catenin was silenced by siRNA interference,and Western blot was used to measure the relative protein expression of β-catenin in A549/DDP cells in the normal serum group,the cisplatin group,the siCTNNB1-235 group,the siCTNNB1-510 group,and the siCTNNB1-547 group. After β-catenin interference,Western blot was used to measure the protein expression levels of β-catenin and Survivin in A549/DDP cells of each group; MTT assay was used to determine the IC50 of cisplatin in A549/DDP cells of each group; Annexin V/PI staining was used to measure the cisplatin-induced apoptosis rate of A549/DDP cells in each group. Results Compared with the normal serum group(1.00),the siCTNBN1-235 group(0.323±0.021) had an inhibition rate of 67% on β-catenin expression(P=0.000). After β-catenin was silenced by RNAi technique,compared with the normal serum group(1.00),the Buzhong Yiqi Decoction+cisplatin group had significantly greater reductions in the protein expression of Survivin(0.247±0.015) and β-catenin(0.257±0.015)(P=0.000,P=0.000). As for the IC50 of cisplatin in A549/DDP cells,compared with the normal serum group(28.330±1.029) μmol/L,serum containing Buzhong Yiqi decoction alone(20.350±1.155) μmol/L or siCTNNB1-235 transient transfection alone(15.577±1.535) μmol/L reduced the IC50 of cisplatin in A549/DDP cells(P=0.000,P=0.000),and the combination of the two methods(10.453±0.999) μmol/L further reduced the IC50 of cisplatin(P=0.000). Compared with the normal serum group(9.130±0.384)%,the siCTNBN1-235 transient transfection+cisplatin group(64.393±0.244)% and the Buzhong Yiqi Decoction+cisplatin group(70.120±0.400)% had a significant increase in overall apoptosis rate(P=0.000,P=0.000). Conclusion Serum containing Buzhong Yiqi Decoction and siβ-catenin transient transfection have a synergistic effect on inhibiting the Wnt/β-catenin signaling pathway and improving cisplatin resistance in lung adenocarcinoma,and Buzhong Yiqi Decoction has a siβ-catenin transient transfection-like effect.

Key words

β-catenin / Survivin / RNAi / lung cancer drug resistance / Buzhong Yiqi Decoction

Cite this article

Download Citations
Li He , Mu Qirui , Wang Zhe , et al . Molecular mechanism of Buzhong Yiqi Decoction in coordination with Siβ-catenin in intervention against cisplatin resistance in lung adenocarcinoma by regulating the Wnt/β-catenin signaling pathway. Journal of Chongqing Medical University. 2024, 49(02): 147-152 https://doi.org/10.13406/j.cnki.cyxb.003420

References

1
Wang ZJ Wu L Li BL,et al. Toripalimab plus chemotherapy for patients with treatment-naive advanced non-small-cell lung cancer:a multicenter randomized phase Ⅲ trial(CHOICE-01)[J]. J Clin Oncol202341(3):651-663.
2
Wang DL Zhao CS Xu F,et al. Cisplatin-resistant NSCLC cells induced by hypoxia transmit resistance to sensitive cells through exosomal PKM2[J]. Theranostics202111(6):2860-2875.
3
牟琪瑞,付权泽,刘春英,等. 补中益气汤含药血清干预A549/DDP细胞Wnt/β-catenin信号通路改善顺铂耐药的机制研究[J]. 时珍国医国药202132(8):1818-1821.
Mu QR Fu QZ Liu CY,et al. Mechanism of serum containing Buzhong Yiqi Decoction on Wnt/β-catenin signaling pathway in A549/DDP cells to improve cisplatin resistance[J]. Lishizhen Med Mater Med Res202132(8):1818-1821.
4
张 颖,高 原,刘春英. 补中益气汤对肺腺癌荷瘤裸鼠A549/DDP细胞顺铂耐药的影响[J]. 中国实验方剂学杂志201925(23):73-78.
Zhang Y Gao Y Liu CY. Effect of Buzhong Yiqi Tang on cisplatin resistance A549/DDP cells in nude mice with lung adenocarcinoma[J]. Chin J Exp Tradit Med Formulae201925(23):73-78.
5
高 原,王 莹,陈 奇,等. 补中益气汤对肺腺癌荷瘤裸鼠移植瘤的抑瘤作用及MRP蛋白表达影响的研究[J]. 时珍国医国药201627(8):1796-1799.
Gao Y Wang Y Chen Q,et al. Study on the inhibitory effect of Buzhong Yiqi Decoction on lung adenocarcinoma transplanted tumor in nude mice and the effect of MRP protein expression[J]. Lishizhen Med Mater Med Res201627(8):1796-1799.
6
钱佳南,孙博云,胡鸿毅. 补中益气汤治疗恶性肿瘤疾病的临床及基础研究进展[J]. 河北中医药学报202136(5):59-64.
Qian JN Sun BY Hu HY. Clinical and basic research progress of Buzhong Yiqi Decoction in treatment of malignant tumor diseases[J]. J Hebei Tradit Chin Med Pharmacol202136(5):59-64.
7
徐国品. 补中益气汤改善肺脾气虚型晚期非小细胞肺癌患者生活质量的临床研究[D]. 合肥:安徽中医药大学,2019
Xu GP. Clinical research of the efficacy of buzhongyiqi Tang in treating lung-spleen qi deficiency advanced non-small cell lung cancer[D]. Hefei:Anhui University of Chinese Medicine,2019
8
周 琳,于 丹,刘春英. 补中益气汤含药血清干预上皮间质转化对A549/DDP细胞凋亡的影响[J]. 中华中医药杂志201732(4):1473-1477.
Zhou L Yu D Liu CY. Effects of Buzhong Yiqi Decoction medicate serum-induced epithelial-mesenchymal transition on apoptosis of A549/DDP cells[J]. China J Tradit Chin Med Pharm201732(4):1473-1477.
9
Liu JQ Xiao Q Xiao JN,et al. Wnt/β-catenin signalling:function,biological mechanisms,and therapeutic opportunities[J]. Signal Transduct Target Ther20227(1):3.
10
Shang S Hua F Hu ZW. The regulation of β-catenin activity and function in cancer:therapeutic opportunities[J]. Oncotarget20178(20):33972-33989.
11
Li JZ Xu SJ Dong H,et al. Altered Wnt5a expression affects radiosensitivity of non-small cell lung cancer via the Wnt/β-catenin pathway[J]. Exp Ther Med202223(1):5.
12
Grossman D McNiff JM Li F,et al. Expression and targeting of the apoptosis inhibitor,survivin,in human melanoma[J]. J Invest Dermatol1999113(6):1076-1081.
13
Sah NK Khan Z Khan GJ,et al. Structural,functional and therapeutic biology of survivin[J]. Cancer Lett2006244(2):164-171.

Comments

PDF(1501 KB)

Accesses

Citation

Detail

Sections
Recommended

/